SRR934935
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.676
- E2F_TARGETS+0.667
- G2M_CHECKPOINT+0.655
- MYC_TARGETS_V2+0.609
- MTORC1_SIGNALING+0.520
- PROTEIN_SECRETION+0.501
- UNFOLDED_PROTEIN_RESPONSE+0.488
- DNA_REPAIR+0.471
- MITOTIC_SPINDLE+0.466
- HYPOXIA+0.404
Top 10 suppressed
- KRAS_SIGNALING_DN-0.479
- BILE_ACID_METABOLISM-0.276
- MYOGENESIS-0.254
- ESTROGEN_RESPONSE_EARLY-0.213
- ESTROGEN_RESPONSE_LATE-0.202
- PANCREAS_BETA_CELLS-0.199
- XENOBIOTIC_METABOLISM-0.176
- INFLAMMATORY_RESPONSE-0.116
- SPERMATOGENESIS-0.097
- PEROXISOME-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934817 | — | — | 0.931 |
| 2 | SRR934902 | — | — | 0.924 |
| 3 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.922 |
| 4 | SRR934813 | — | — | 0.921 |
| 5 | A21476BD-0550-4D87-80EA-6E1454E0896D | — | — | 0.917 |
| 6 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.915 |
| 7 | ECCC2F18-409F-41BA-B49F-95B23893B80B | — | — | 0.911 |
| 8 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.905 |
| 9 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.902 |
| 10 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.676 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.667 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.655 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.609 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.520 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.501 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.488 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.471 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.466 | Inavolisib | — uncovered |
| HYPOXIA | 0.404 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.401 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.381 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.367 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.325 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.314 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.314 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.301 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.278 | Inavolisib | — uncovered |
| APOPTOSIS | 0.271 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.256 | Inavolisib | — uncovered |